Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986737 | 0.94 | CYP2C9 (0.67) | CYP2C9 | |
| SCHEMBL2974718 | 0.92 | CYP2C9 (0.64) | CYP2C9 | |
| SCHEMBL2981758 | 0.89 | CYP2C9 (0.67) | CYP2C9 | |
| SCHEMBL2974846 | 0.89 | CYP2C9 (0.75) | CYP2C9 | |
| SCHEMBL2969989 | 0.88 | CYP2C9 (0.68) | CYP2C9 | |
| SCHEMBL2987126 | 0.86 | CYP2C9 (0.75) | CYP2C9 | |
| SCHEMBL2969837 | 0.86 | — | — | |
| SCHEMBL2985423 | 0.85 | CYP2C9 (0.68) | CYP2C9 | |
| SCHEMBL2986545 | 0.85 | CYP2C9 (0.68) | CYP2C9 | |
| SCHEMBL2972749 | 0.85 | CYP2C9 (0.72) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | claimed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | claimed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7786161-B2 | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1431267-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | PTGER2, PTGER4, PTGER1 | CYP2C9 369/4885 |
| US-20060258728-A1 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | PTGER2, PTGER4, PTGER1 | CYP2C9 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.